BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28750139)

  • 1. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.
    Isaksson K; Nielsen K; Mikiver R; Nieweg OE; Scolyer RA; Thompson JF; Ingvar C
    J Surg Oncol; 2018 Sep; 118(4):599-605. PubMed ID: 30196533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
    Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
    Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
    Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity.
    Mahiques Santos L; Oliver Martinez V; Alegre de Miquel V
    Actas Dermosifiliogr; 2014; 105(1):60-8. PubMed ID: 24021663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
    Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR
    J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does the mitotic index impact patients with T1 melanoma? Comparison between the 7th and 8th edition of the American Joint Committee on Cancer melanoma staging system.
    Antonialli AZ; Bertolli E; de Macedo MP; Pinto CAL; Calsavara VF; Neto JPD
    An Bras Dermatol; 2020; 95(6):691-695. PubMed ID: 33008658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
    Kesmodel SB; Karakousis GC; Botbyl JD; Canter RJ; Lewis RT; Wahl PM; Terhune KP; Alavi A; Elder DE; Ming ME; Guerry D; Gimotty PA; Fraker DL; Czerniecki BJ; Spitz FR
    Ann Surg Oncol; 2005 Jun; 12(6):449-58. PubMed ID: 15864482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.
    Rousseau DL; Ross MI; Johnson MM; Prieto VG; Lee JE; Mansfield PF; Gershenwald JE
    Ann Surg Oncol; 2003 Jun; 10(5):569-74. PubMed ID: 12794025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis.
    Kocsis A; Karsko L; Kurgyis Z; Besenyi Z; Pavics L; Dosa-Racz E; Kis E; Baltas E; Ocsai H; Varga E; Bende B; Varga A; Mohos G; Korom I; Varga J; Kemeny L; Nemeth IB; Olah J
    Pathol Oncol Res; 2020 Jul; 26(3):1861-1868. PubMed ID: 31792874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.
    Sondak VK; Taylor JM; Sabel MS; Wang Y; Lowe L; Grover AC; Chang AE; Yahanda AM; Moon J; Johnson TM
    Ann Surg Oncol; 2004 Mar; 11(3):247-58. PubMed ID: 14993019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy?
    Kirkland EB; Zitelli JA
    Dermatol Surg; 2014 Sep; 40(9):937-45. PubMed ID: 25072127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.
    Bartlett EK; Gimotty PA; Sinnamon AJ; Wachtel H; Roses RE; Schuchter L; Xu X; Elder DE; Ming M; Elenitsas R; Guerry D; Kelz RR; Czerniecki BJ; Fraker DL; Karakousis GC
    Ann Surg Oncol; 2014 Feb; 21(2):643-9. PubMed ID: 24121883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8
    Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM
    J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
    Mandalà M; Galli F; Cattaneo L; Merelli B; Rulli E; Ribero S; Quaglino P; De Giorgi V; Pigozzo J; Sileni VC; Chirco A; Ferrucci PF; Occelli M; Imberti G; Piazzalunga D; Massi D; Tondini C; Queirolo P;
    J Am Acad Dermatol; 2017 Feb; 76(2):264-273.e2. PubMed ID: 27847125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.